Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N6-methyladenosine–mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling
Yun Liu, Jun Zhang, Fang Cao, Xiaobao Dong, Jie Li, Yanna Cao, Zhanglin Li, Yan Guo, Jie Yan, Yuanyuan Liu, Qiang Zhao
Yun Liu, Jun Zhang, Fang Cao, Xiaobao Dong, Jie Li, Yanna Cao, Zhanglin Li, Yan Guo, Jie Yan, Yuanyuan Liu, Qiang Zhao
View: Text | PDF
Research Article Oncology

N6-methyladenosine–mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling

  • Text
  • PDF
Abstract

Neuroblastomas have shed light on the differentiation disorder that is associated with spontaneous regression or differentiation in the same tumor at the same time. Long noncoding RNAs (lncRNAs) actively participate in a broad spectrum of biological processes. However, the detailed molecular mechanisms underlying lncRNA regulation of differentiation in neuroblastomas remain largely unknown. Here, we sequenced clinical samples of ganglioneuroma, ganglioneuroblastoma, and neuroblastoma. We compared transcription profiles of neuroblastoma cells, ganglion cells, and intermediate state cells; verified the profiles in a retinoic acid–induced cell differentiation model and clinical samples; and screened out the lncRNA ADAMTS9 antisense RNA 2 (ADAMTS9-AS2), which contributed to neuroblastoma differentiation. ADAMTS9-AS2 upregulation in neuroblastoma cell lines inhibited proliferation and metastatic potential. Additional mechanistic studies illustrated that the interactions between ADAMTS9-AS2 and LIN28B inhibited the association between LIN28B and primary let-7 (pri-let-7) miRNA, then released pri-let-7 into cytoplasm to form mature let-7, resulting in the inhibition of oncogene MYCN activity that subsequently affected cancer stemness and differentiation. Furthermore, we showed that the observed differential expression of ADAMTS9-AS2 in neuroblastoma cells was due to N6-methyladenosine methylation. Finally, ADAMTS9-AS2 upregulation inhibited proliferation and cancer stem-like capabilities in vivo. Taken together, these results show that ADAMTS9-AS2 loss leads to malignant neuroblastoma by increasing metastasis and causing dysfunctional differentiation.

Authors

Yun Liu, Jun Zhang, Fang Cao, Xiaobao Dong, Jie Li, Yanna Cao, Zhanglin Li, Yan Guo, Jie Yan, Yuanyuan Liu, Qiang Zhao

×

Figure 6

ADAMTS9-AS2 expression levels in neuroblastoma cells is regulated by m6A modification.

Options: View larger image (or click on image) Download as PowerPoint

ADAMTS9-AS2 expression levels in neuroblastoma cells is regulated by m6...
(A) M6A RIP and qRT-PCR analyses were conducted in neuroblastoma cells (n = 3). (B) Graphs showing enrichment of ADAMTS9-AS2 in the METTL3 or ALKBH5 immunoprecipitated RNA fraction of SK-N-Be2 cells (n = 3). (C) RNA pulldown assay showed the interaction between ADAMTS9-AS2 and METTL3/ALKBH5. (D) METTL3 and ALKBH5 expression in 5 neuroblastoma cell lines. (E) ADAMTS9-AS2 and MYCN expression levels were evaluated in neuroblastoma cells overexpressing METTL3 or ALKBH5 (n = 3). (F) The expression level of ADAMTS9-AS2 and MYCN was assessed in SK-N-Be2 cells with ALKBH5 knockdown and SK-N-SH cells with METTL3 knockdown (n = 3). (G) pcDNA3.1+-, ADAMTS9-AS2–, and ADAMTS9-AS2+siMETTL3–transfected SK-N-SH cells and siNC-, siADAMTS9-AS2–, and siADAMTS9-AS2+siALKBH5–transfected SK-N-Be2 cells were subjected to measurement of ADAMTS9-AS2 and MYCN expression. Experiments were conducted in triplicate and data are presented as mean ± SD. Statistical differences were calculated using unpaired 2-tailed Student’s t test except for multiple-group comparisons for which 1-way ANOVA was used. *P < 0.05; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts